Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O
InChI
InChIKey=FEWJPZIEWOKRBE-JCYAYHJZSA-N
InChI=1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/t1-,2-/m1/s1
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tartaric acid is found in many plants such as grapes, tamarinds, pineapples, mulberries and so on. Wine lees (called mud in the US), the sediment collected during the fermentation of grapes, contains potassium bitartrate (potassium hydrogen tartrate) as its major component. L-(+)-tartaric acid is an enantiomer of tartaric acid. Twenty five years before the tetrahedral structure for carbon was proposed in 1874 to explain the optical activity and other properties of organic compounds, Louis Pasteur discovered the existence of enantiomerism in tartaric acid. L-(+)-tartaric acid is widely used in food and beverage as acidity regulator with E number E334.
Approval Year
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator​
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
Page: 59.0 |
no | |||
yes [Ki 91 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 93.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Cinchoninium L-tartrate tetrahydrate. | 2001 Dec |
|
Production and chemiluminescent free radical reactions of glyoxal in lipid peroxidation of linoleic acid by the ligninolytic enzyme, manganese peroxidase. | 2001 Dec |
|
LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. | 2001 Dec 15 |
|
Cell-surface recognition of biotinylated membrane proteins requires very long spacer arms: an example from glucose-transporter probes. | 2001 Jan 8 |
|
[Acid phosphatase, ACP (EC 3.1.3.2)]. | 2001 Nov |
|
The hygroscopic properties of dicarboxylic and multifunctional acids: measurements and UNIFAC predictions. | 2001 Nov 15 |
|
The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation. | 2002 Apr |
|
New materials for ESR dosimetry. | 2002 Apr |
|
Acid phosphatases. | 2002 Apr |
|
Stereoselective synthesis of myo-inositol via ring-closing metathesis: a building block for glycosylphosphatidylinositol (GPI) anchor synthesis. | 2002 Apr 18 |
|
Towards atomic resolution with crystals grown in gel: the case of thaumatin seen at room temperature. | 2002 Aug 1 |
|
Thermophysical properties of pharmaceutically compatible buffers at sub-zero temperatures: implications for freeze-drying. | 2002 Feb |
|
Retention of anions on silica-based metalloporphyrin stationary phases. | 2002 Feb |
|
Ergotamine-induced anorectal strictures: report of five cases. | 2002 Feb |
|
Diaquabis[mu-(R,R)-tartrato-kappa4O1,O2:O3,O4]dinickel(II) trihydrate. | 2002 Feb |
|
The microphthalmia transcription factor and the related helix-loop-helix zipper factors TFE-3 and TFE-C collaborate to activate the tartrate-resistant acid phosphatase promoter. | 2002 Feb |
|
Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells. | 2002 Feb |
|
Screening method for inherited disorders of purine and pyrimidine metabolism by capillary electrophoresis with reversed electroosmotic flow. | 2002 Feb 15 |
|
Therapy and disease concepts: the history (and future?) of antimony in cancer. | 2002 Jan |
|
Some comparative aspects of the pharmacokinetics of tylosin in buffaloes and cattle. | 2002 Jan |
|
Anaerobaculum mobile sp. nov., a novel anaerobic, moderately thermophilic, peptide-fermenting bacterium that uses crotonate as an electron acceptor, and emended description of the genus Anaerobaculum. | 2002 Jan |
|
Crystal structure analysis of the exocytosis-sensitive phosphoprotein, pp63/parafusin (phosphoglucomutase), from Paramecium reveals significant conformational variability. | 2002 Jan 11 |
|
Revision of absolute configuration of enantiomeric (methylenecyclopropyl)carbinols obtained from (R)-(-)- and (S)-(+)-epichlorohydrin and methylenetriphenylphosphorane. Implications for reaction mechanism and improved synthesis of antiviral methylenecyclopropane analogues of nucleosides. | 2002 Jan 11 |
|
From local adsorption stresses to chiral surfaces: (R,R)-tartaric acid on Ni(110). | 2002 Jan 23 |
|
Effect of antibiotics on in vitro and in vivo avian cartilage degradation. | 2002 Jan-Mar |
|
A simple spectrophotometric method for the determination of copper in industrial, environmental, biological and soil samples using 2,5-dimercapto-1,3,4-thiadiazole. | 2002 Jul |
|
High frequency of phenotypic deviations in Physcomitrella patens plants transformed with a gene-disruption library. | 2002 Jul 18 |
|
Boronic acid receptors for alpha-hydroxycarboxylates: high affinity of Shinkai's glucose receptor for tartrate. | 2002 Jul 26 |
|
Engineering the substrate specificity of D-amino-acid oxidase. | 2002 Jul 26 |
|
Improving the labeling of S-acetyl NHS-MAG(3)-conjugated morpholino oligomers. | 2002 Jul-Aug |
|
Effects of cyclic pressure on bone marrow cell cultures. | 2002 Jun |
|
Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. | 2002 Jun |
|
Stereoselective radical reactions of some tartaric and glyceric acid derivatives. | 2002 Jun 13 |
|
The separation of racemic crystals into enantiomers by chiral block copolymers. | 2002 Jun 3 |
|
Determination of the side-products formed during the nitroxide-mediated bleach oxidation of glucose to glucaric acid. | 2002 Jun 5 |
|
Recruitment, augmentation and apoptosis of rat osteoclasts in 1,25-(OH)2D3 response to short-term treatment with 1,25-dihydroxyvitamin D3 in vivo. | 2002 Jun 7 |
|
Gender- and age-related differences in osteoclast formation from circulating precursors. | 2002 Mar |
|
Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice. | 2002 Mar 1 |
|
Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. | 2002 Mar 18 |
|
Release of an acid phosphatase activity during lily pollen tube growth involves components of the secretory pathway. | 2002 May |
|
Use of disposable GRC electrodes for the detection of phenol and chlorophenols in liquid chromatography. | 2002 May |
|
Crystallization and preliminary X-ray crystallographic analysis of UDP-N-acetylglucosamine acyltransferase from Helicobacter pylori. | 2002 May |
|
Potassium antimonyl tartrate induces reactive oxygen species-related apoptosis in human myeloid leukemic HL60 cells. | 2002 May |
|
Synovial macrophage-osteoclast differentiation in inflammatory arthritis. | 2002 Oct |
|
Ectonucleotide diphosphohydrolase activity in Crithidia deanei. | 2002 Oct |
|
Formation of methylantimony species by an aerobic prokaryote: Flavobacterium sp. | 2002 Oct |
|
Effects of sigma(1) receptor ligand MS-377 on D(2) antagonists-induced behaviors. | 2002 Oct |
|
Development of high-affinity ligands and photoaffinity labels for the D-fructose transporter GLUT5. | 2002 Oct 15 |
|
Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. | 2002 Oct 25 |
|
Symmetric and helical growth of polyacetylene fibers over a single copper crystal derived from copper tartrate decomposition. | 2002 Sep 5 |
Sample Use Guides
L-( )-tartaric acid as a food additive. Acceptable Daily Intake: 0-30 mg/kg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3540104
After incubation in medium containing 50 mM L( )-tartaric acid, osteoclasts and chondroclasts were heavily stained with reaction product.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:34:10 GMT 2025
by
admin
on
Mon Mar 31 17:34:10 GMT 2025
|
Record UNII |
W4888I119H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
INS-334
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
||
|
JECFA EVALUATION |
L(+)-TARTARIC ACID
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
||
|
CFR |
21 CFR 184.1099
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-334
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
||
|
DSLD |
3118 (Number of products:16)
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
132950
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200861
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
m10475
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | Merck Index | ||
|
37578
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | RxNorm | ||
|
187
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
444305
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
C029768
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
TARTARIC ACID
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
DTXSID8023632
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
15674
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
100000078782
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
2566
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
C47744
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
526-83-0
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
30929
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
15671
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
50562
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
W4888I119H
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
SUB12604MIG
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
DB09459
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
87-69-4
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
62778
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
W4888I119H
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
1643340
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
1314221
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
ALTERNATIVE | |||
|
201-766-0
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY | |||
|
463
Created by
admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |